Alnylam Pharmaceuticals (ALNY) – Research Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) in the last few weeks:

• 10/8/2026 – Alnylam Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $350.00 to $345.00. They now have an “outperform” rating on the stock.
• 10/5/2026 – Alnylam Pharmaceuticals was upgraded by Zacks Research from “hold” to “strong-buy”.
• 9/30/2026 – Alnylam Pharmaceuticals had its “neutral” rating reaffirmed by Cantor Fitzgerald.
• 9/30/2026 – Alnylam Pharmaceuticals had its price target lowered by JPMorgan Chase & Co. from $375.00 to $369.00. They now have an “overweight” rating on the stock.
• 9/21/2026 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $455.00 price target on the stock.
• 9/8/2026 – Alnylam Pharmaceuticals had its price target raised by Jefferies Financial Group Inc. from $230.00 to $260.00. They now have a “hold” rating on the stock.
• 9/2/2026 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $455.00 price target on the stock.
• 8/31/2026 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by Sanford C. Bernstein.
• 8/31/2026 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by TD Cowen.
• 8/31/2026 – Alnylam Pharmaceuticals had its “outperform” rating reaffirmed by BMO Capital Markets.
• 8/25/2026 – Alnylam Pharmaceuticals had its “outperform” rating reaffirmed by Sanford C. Bernstein. They now have a $376.00 price target on the stock.
• 8/19/2026 – Alnylam Pharmaceuticals is now covered by BMO Capital Markets. They set an “outperform” rating and a $318.00 price target on the stock.
• 8/18/2026 – Alnylam Pharmaceuticals was upgraded by BMO Capital Markets to “strong-buy”.
• 8/14/2026 – Alnylam Pharmaceuticals had its price target lowered by Wells Fargo & Company from $316.00 to $256.00. They now have an “equal weight” rating on the stock.

Insider Activity

In related news, EVP Bryan Supran sold 1,758 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the sale, the executive vice president owned 12,807 shares of the company’s stock, valued at approximately $2,905,652.16. This trade represents a 12.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi), a biological process that can selectively reduce the production of disease-causing proteins. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include ONPATTRO (patisiran), an RNAi therapy for hereditary transthyretin-mediated amyloidosis with polyneuropathy; GIVLAARI (givosiran), for acute hepatic porphyria; OXLUMO (lumasiran), for primary hyperoxaluria type 1; and AMVUTTRA (vutrisiran), for transthyretin-mediated amyloidosis.